Project Grant R01HL174505
Award Date
8/15/24
Completion Date
5/31/29
Dollars Obligated
$2M
Federal Agency
National Heart Lung and Blood Institute
Awardee
Mayo Clinic (Y2K4F9RPRRG7)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $732,225 to investigate the role of mitochondrial DNA (mtDNA) variants in the pathogenesis of asthma. The research aims to: 1) identify associations between mtDNA single nucleotide variants (SNVs) and asthma risk/traits, and examine how risk variants influence mitochondrial function in cells from asthmatic and healthy individuals, and 2)...
This Project Grant award for $355,935 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) supports the development of a novel, oral immunoregulatory therapeutic for the treatment of asthma. The primary objectives are to characterize the therapeutic efficacy and dosing regimen of the compound in mouse models of asthma, and to evaluate its ability to modulate immune function and suppress inflammation in human...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $616,814 to the President and Fellows of Harvard College, Harvard T.H. Chan School of Public Health, to conduct research on the role of microRNAs in regulating airway smooth muscle function and their contribution to asthma. The overarching goal is to establish the in vivo impact of key microRNAs in regulating airway smooth muscle proliferation,...
This federal Project Grant award of $613,934 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research into the role of the aryl hydrocarbon receptor (AhR) signaling pathway in regulating airway smooth muscle responses during inflammation and asthma. The key objectives are to: 1) Determine the mechanisms of AhR expression and regulation in human airway smooth muscle under inflammatory conditions; 2) Investigate...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $740,709 to the University of Utah to conduct research on how early-life viral infections can lead to the development of childhood asthma. The key objectives are to define the cellular and molecular mechanisms by which viral-induced inflammation programs hyperactivated type 2 innate lymphoid cells (ILC2s) in the lung, and determine if these hyperactivated ILC2s...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $636,843 to The Regents of the University of California, San Francisco (UCSF) to conduct research on targeting the stromal niche for tissue-resident lymphocytes in asthma. The research aims to characterize a targetable stromal factor that alters immune cell accumulation in the lung and define the downstream effects on airway epithelial...
The National Heart, Lung, and Blood Institute (NHLBI), under CFDA 93.837 - Cardiovascular Diseases Research, awarded a $387,116 Project Grant to the University of South Florida. The 5-year grant, effective May 1, 2025, supports research to define the neural mechanisms by which house dust mite (HDM) exposure triggers airway hyperreactivity, a key characteristic of asthma. The research aims to identify the specific sensory nerve subtypes and signaling pathways activated by HDM that lead to...
The federal Project Grant award R56AI192629 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program. The $250,000 award to The General Hospital Corporation (doing business as Massachusetts General Hospital) aims to identify key pathways that mediate the survival and maintenance of lung-resident memory T helper type 2 (Th2) cells in allergic asthma. The research seeks to determine if...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $777,497.00 to The Washington University to study how the circadian clock mediates the adult age, pro-resolution response to viral asthma triggers. The research aims to clarify how the circadian clock operating within alveolar macrophages and airway epithelial cells promotes the resolution of viral inflammation and normal repair...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $347,608 to Biotherapeutics, Inc. to develop a novel, oral, once-daily, immunoregulatory therapeutic for the treatment of asthma. The key objectives are to: 1) characterize the therapeutic efficacy and route of administration of the drug candidate in mouse models of asthma, and 2) determine the translational ability of the therapeutic...